Why should regulators consider using patient preferences in benefit-risk assessment?

Pharmacoeconomics. 2014 Jan;32(1):1-4. doi: 10.1007/s40273-013-0118-6.

Authors

Janine A van Til¹, Maarten J Ijzerman

Affiliation

¹ Department of Health Technology and Services Research, University of Twente, PO Box 217, 7500 AE, Enschede, The Netherlands, j.a.vantil@utwente.nl.

PMID: 24288209
DOI: 10.1007/s40273-013-0118-6

No abstract available

Publication types

Editorial

MeSH terms

Decision Support Techniques*
Drug Therapy / economics
Drug-Related Side Effects and Adverse Reactions
Europe
Government Regulation
Humans
Patient Preference* / economics
Patient Preference* / legislation & jurisprudence
Risk Assessment
United States
United States Food and Drug Administration